236 related articles for article (PubMed ID: 17973859)
1. Upregulated endothelin system in diabetic vascular dysfunction and early retinopathy is reversed by CPU0213 and total triterpene acids from Fructus Corni.
Su W; Dai DZ; Liu HR; Na T; Dai Y
Clin Exp Pharmacol Physiol; 2007 Dec; 34(12):1228-33. PubMed ID: 17973859
[TBL] [Abstract][Full Text] [Related]
2. Sildenafil improves diabetic vascular activity through suppressing endothelin receptor A, iNOS and NADPH oxidase which is comparable with the endothelin receptor antagonist CPU0213 in STZ-injected rats.
Luo L; Dai DZ; Cheng YS; Zhang Q; Yuan WJ; Dai Y
J Pharm Pharmacol; 2011 Jul; 63(7):943-51. PubMed ID: 21635260
[TBL] [Abstract][Full Text] [Related]
3. The endothelin receptor antagonist CPU0213 is more effective than aminoguanidine to attenuate isoproterenol-induced vascular abnormality by suppressing overexpression of NADPH oxidase [correction of oxidas], ETA, ETB, and MMP9 in the vasculature.
Xu J; Li N; Dai DZ; Yu F; Dai Y
J Cardiovasc Pharmacol; 2008 Jul; 52(1):42-8. PubMed ID: 18594475
[TBL] [Abstract][Full Text] [Related]
4. A novel endothelin receptor antagonist CPU0213 improves diabetic cardiac insufficiency attributed to up-regulation of the expression of FKBP12.6, SERCA2a, and PLB in rats.
Qi MY; Xia HJ; Dai DZ; Dai Y
J Cardiovasc Pharmacol; 2006 Jun; 47(6):729-35. PubMed ID: 16810072
[TBL] [Abstract][Full Text] [Related]
5. Hypercholesterolaemia induces early renal lesions characterized by upregulation of MMP-9 and iNOS and ET(A)R: alleviated by a dual endothelin receptor antagonist CPU0213 and simvastatin.
Luo L; Zheng YF; Dai Y; Dai DZ
J Pharm Pharmacol; 2009 Jun; 61(6):775-80. PubMed ID: 19505368
[TBL] [Abstract][Full Text] [Related]
6. Total triterpene acids, active ingredients from Fructus Corni, attenuate diabetic cardiomyopathy by normalizing ET pathway and expression of FKBP12.6 and SERCA2a in streptozotocin-rats.
Qi MY; Liu HR; Dai DZ; Li N; Dai Y
J Pharm Pharmacol; 2008 Dec; 60(12):1687-94. PubMed ID: 19000375
[TBL] [Abstract][Full Text] [Related]
7. An endothelin type A receptor antagonist reverses upregulated VEGF and ICAM-1 levels in streptozotocin-induced diabetic rat retina.
Masuzawa K; Goto K; Jesmin S; Maeda S; Miyauchi T; Kaji Y; Oshika T; Hori S
Curr Eye Res; 2006 Jan; 31(1):79-89. PubMed ID: 16421022
[TBL] [Abstract][Full Text] [Related]
8. The role of the sodium hydrogen exchanger-1 in mediating diabetes-induced changes in the retina.
Cukiernik M; Hileeto D; Downey D; Evans T; Khan ZA; Karmazyn M; Chakrabarti S
Diabetes Metab Res Rev; 2004; 20(1):61-71. PubMed ID: 14737747
[TBL] [Abstract][Full Text] [Related]
9. Down-regulation of FKBP12.6 and SERCA2a contributes to acute heart failure in septic shock and is related to an up-regulated endothelin signalling pathway.
He HB; Yu F; Dai DZ; Dai Y
J Pharm Pharmacol; 2007 Jul; 59(7):977-84. PubMed ID: 17637193
[TBL] [Abstract][Full Text] [Related]
10. Regulation of retinal hemodynamics in diabetic rats by increased expression and action of endothelin-1.
Takagi C; Bursell SE; Lin YW; Takagi H; Duh E; Jiang Z; Clermont AC; King GL
Invest Ophthalmol Vis Sci; 1996 Nov; 37(12):2504-18. PubMed ID: 8933767
[TBL] [Abstract][Full Text] [Related]
11. Diabetes-induced vascular dysfunction in the retina: role of endothelins.
Deng D; Evans T; Mukherjee K; Downey D; Chakrabarti S
Diabetologia; 1999 Oct; 42(10):1228-34. PubMed ID: 10525664
[TBL] [Abstract][Full Text] [Related]
12. CPU0213, a novel endothelin receptor antagonist, ameliorates septic renal lesion by suppressing ET system and NF-kappaB in rats.
He HB; Dai DZ; Dai Y
Acta Pharmacol Sin; 2006 Sep; 27(9):1213-21. PubMed ID: 16923343
[TBL] [Abstract][Full Text] [Related]
13. Vascular endothelial growth factor in diabetes induced early retinal abnormalities.
Cukiernik M; Hileeto D; Evans T; Mukherjee S; Downey D; Chakrabarti S
Diabetes Res Clin Pract; 2004 Sep; 65(3):197-208. PubMed ID: 15331199
[TBL] [Abstract][Full Text] [Related]
14. Effect of endothelin dual receptor antagonist on VEGF levels in streptozotocin-induced diabetic rat retina.
Masuzawa K; Jesmin S; Maeda S; Zaedi S; Shimojo N; Miyauchi T; Goto K
Exp Biol Med (Maywood); 2006 Jun; 231(6):1090-4. PubMed ID: 16741055
[TBL] [Abstract][Full Text] [Related]
15. Characterization of endothelin-1 and nitric oxide generating systems in corpus luteum-derived endothelial cells.
Klipper E; Gilboa T; Levy N; Kisliouk T; Spanel-Borowski K; Meidan R
Reproduction; 2004 Oct; 128(4):463-73. PubMed ID: 15454641
[TBL] [Abstract][Full Text] [Related]
16. Effects of a selective endothelin a receptor antagonist on the expressions of iNOS and eNOS in the heart of early streptozotocin-induced diabetic rats.
Jesmin S; Zaedi S; Maeda S; Yamaguchi I; Goto K; Miyauchi T
Exp Biol Med (Maywood); 2006 Jun; 231(6):925-31. PubMed ID: 16741025
[TBL] [Abstract][Full Text] [Related]
17. Increase in tissue endothelin-1 and ETA receptor levels in human aortic valve stenosis.
Peltonen T; Taskinen P; Näpänkangas J; Leskinen H; Ohtonen P; Soini Y; Juvonen T; Satta J; Vuolteenaho O; Ruskoaho H
Eur Heart J; 2009 Jan; 30(2):242-9. PubMed ID: 19008257
[TBL] [Abstract][Full Text] [Related]
18. Effects of an endothelin receptor antagonist on a model of hypertensive retinopathy.
McDonald L; Lee GR; Degooyer TE; McDonald D; Canning P; Kelso EJ; McDermott BJ; Stitt AW
Ophthalmic Res; 2010; 43(2):99-107. PubMed ID: 19829016
[TBL] [Abstract][Full Text] [Related]
19. Intravitreal administration of endothelin type A receptor or endothelin type B receptor antagonists attenuates hypertensive and diabetic retinopathy in rats.
Alrashdi SF; Deliyanti D; Wilkinson-Berka JL
Exp Eye Res; 2018 Nov; 176():1-9. PubMed ID: 29944850
[TBL] [Abstract][Full Text] [Related]
20. Downregulation of renal endothelin-converting enzyme 2 expression in early autoimmune diabetes.
Ortmann J; Nett PC; Celeiro J; Hofmann-Lehmann R; Tornillo L; Terracciano LM; Barton M
Exp Biol Med (Maywood); 2006 Jun; 231(6):1030-3. PubMed ID: 16741043
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
